

BIOHK2021

Biotech Kaleidoscope - Infinite Possibilities

BIOHK2021

香港國際生物科技展

Foreword

BIOHK will bring together the world's leading, established and most innovative stakeholders in biotech, pharma and finance as they collaborate in exploring the future of Hong Kong's role as a Biotech hub for the advancement of Biotech benefits worldwide. **BIOHK is expected to become a signature event in Hong Kong.**

Why Biotech in Hong Kong ?

Historically, the cyclical nature of biotech revolutions brought a fresh surge of innovation every two decades.

Hong Kong is at the nexus of converging goals and visions between key regional and global industry, finance, academic, research and innovation sectors.

This is the **right moment** to capitalize on the Hong Kong Special Administrative Region's unique position as a strategic global hub for biotech.

Hong Kong Being the Key Strategic Role

- **President Xi Jinping** directed state agencies to help Hong Kong become an **international** innovation hub
- Hong Kong possesses extensive experience in commercializing innovative technology for industrial application and branding & marketing
- See more details in Appendix V

Hong Kong Offers

- World-class R&D capability
- World's top three Financial Centers for Venture Capital
- Gateway to vast China market
- Strong International Investor Base
- *See more in Appendix VI*

Event Details

Dates: 10 - 13 March 2021 (Wednesday – Saturday)

Venue: AsiaWorld-Expo

Exhibition: Around 300 Exhibition Booths (could be more)

Speakers: Over 150

Expected visitors: Over 7,000

Highlights:

Exhibition	Conference & Pitch Session
One2One Partnering	Welcome Reception
Public Day	Gala Dinner & Awards Ceremony
Greater Bay Area Tour	

Event Highlights

Exhibition

> Showcase and Connect

Showcase and Connect your company to the international biotech scene and vast China market for trading and collaboration opportunities.

Conference

> Share and Inspire

Share and Inspire through invaluable discussions about the latest regional and international research findings and industry trends.

One2One Partnering

> Promote and Establish

Promote and Establish your company as 'one to watch' in the biotech marketplace by identifying and meeting prospective partners.



Exhibition - Showcase and Connect

Reach the leading, established, most innovative and freshest voices in Big Health Industry, Biotech, Drug Development and Pharma. Pitch and Connect your company to the international biotech scene and vast China market for trading and collaboration opportunities.

- *Present your Brand and Innovations*
- *Reinforce Positioning*
- *Build Brand Awareness*
- *Extend Brand Reach*
- *Advertise to Target Market(s)*
- *Valuable Face-Time*
- *Connections with Related Parties*
- *Extend Visibility*
- *Expand Customer Base*
- *Business to Business Trading*

Conference - Share and Inspire

A platform for in-depth discussions and mapping of the latest regional and international industry and research findings and trends.

■ Enhance Your Awareness

■ Attain the Latest Know-how

■ Gain Unique Insights

■ Biotech seminars

Sessions will showcase leading thinkers, international scientists, entrepreneurs and investors from diverse disciplines coming together to exchange research findings, ideas and professional development experiences across a wide range of topics in interactive sessions, panel discussions and podium talks.

We are expecting more than **7,000** participants, including over **150** speakers across multiple panel sessions

**Conference Topics see appendix IV*

Keynote Speakers



HAN Ji Sheng

Director, Institute of Neuroscience, Peking University



LEUNG Chun Ying

Vice Chairman, National Committee of the CPPCC



SONG Ruilin

Chairman, China Pharmaceutical Innovation and Research Development Association



WANG Yu

Former Director General, Chinese Center for Disease Control and Prevention (China CDC)



YANG Huan Ming

Co-founder, Director and Chairman of BGI Group

Speakers



GLASS David, Jonathan

Vice President, Research, Regeneron Pharmaceuticals, Inc.



GRAY Nancy

President & CEO, The Gordon Research Conferences



ZHOU Guo Ying, Grace

President, Shenzhen International Institute for Biomedical Research



JOHNSON E. Bruce

Chief Clinical Research Officer, Dana-Farber Cancer Institute



YUNG Wai-Kwan, Alfred

Professor, Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center



ZHAO Guo Ping

Professor, Shanghai Institute for Biological Sciences, CAS



BIRUKOV G. Konstantin

Anesthesiology Endowed Professor, Entrepreneurial Research and Professor of Physiology

One2One Partnering - Promote and Establish

Explore and secure collaborative partnerships and cross-border possibilities.
Promote and establish your company as “one to watch” in the biotech marketplace by identifying and meeting prospective partners.

- Network with industry practitioners, academicians, reputable biopharma firms and educational institutions
- Spot your prospective partners – investors, analysts and partnering companies
- Form valuable partnerships with leading biotech firms
- Meet and greet with high-level executives
- Build promising partnerships in a broad-spectrum marketplace
- Investors have opportunities to extend business propositions to inventors
- Explore Hong Kong as the home for your next business or start-up

Other Highlights

Public Day

> Education and Promote

The last day of the convention will be open to public. Public visitors are able to participate in public talks and exhibition. Exhibitors can sell their products to the public.

Greater Bay Area Tour

> More Opportunities in GBA

Out of China's 199 science parks, 111 are biotechnology-related, with 93 concentrated in the Guangzhou area. Get an in depth look into this high-tech research and manufacturing epicentre by joining our Greater Bay Area tour.

Gala Dinner

> Awards Ceremony

Held in the last day evening, it is expected government head, executives, professionals and guests from Hong Kong, GBA and Central Federal Government, together with BIOHK Convention delegates will participate in this grand event.



Target Audiences

Investors

- Biotech Entrepreneurs
- CRO
- CMO
- Academia
- R&D Organizations
- Government
- Research Labs
- Leading Consultancy Services
- Science / Industrial Parks
- Incubation Centers
- Clinical & Education Trial Centers
- Diagnostics & Medical Devices

Biological and Startups

- Biopharmaceutical & Drug Developers
- Clinical Research & Lab Services
- Regenerative Medicine
- Agriculture and Fishery Biotechnology
- Bio manufacturing Platform Technologies
- Genomics / Genetics
- Marine Biotechnology
- Generic Drugs, API and Intermediates
- Smart Hospitals
- Investment, Legal and Financial Services
- And more...

Health and medical industry



Presidents of BIOHK2021



Professor Albert Cheung-hoi YU, PhD, JP
President, BIOHK2021
Chairman, Hong Kong Biotechnology Organization
Chairman, Guangdong-Hong Kong-Macao Greater
Bay Area Biotechnology Alliance
Professor, Peking University



Mr. CHEN Tony
Co-president, BIOHK2021
Chairman, The Bayhelix Group
Partner, Jones Day Shanghai



Mr. CHEN Ping
Co-president, BIOHK2021
Founding Partner, Ausvic Capital Limited
Life Honorary President, Hong Kong New Territories
Regional Affairs Consultant Association
Standing director, China Real Estate Developers
and Investors Association
General secretary, Guangdong-Hong Kong-Macao
Greater Bay Area Finance Institute

Organizing Committees (1)



BASu Juan
President and CEO,
National Foundation for
Cancer Research



CHAN Sabrina
Senior Executive Director,
Hong Kong Association of
the Pharmaceuticals Industry



CHAU Chi Wai, Wilton
Chairman, Pan Asia Venture
Development Platform (PAVD)



CHEN Michelle
VP & Head of Corporate
Development, WuXi Biologics



CHEN Wei Jie, Danny
Investment Director, Affix
Capital



CHUNG Pui Sing, John
Former superintendent,
Hong Kong Police Force



HAO Martha
Business Consultant of Wise
Ally Holding Ltd.



HAU Desmond
CEO, Pangenix Inc and
DiagCor Life Science Ltd.



HSIAO Wen Luan, Wendy
Professor, State Key Laboratory of
Quality Research in Chinese Medicine,
Macau University of
Science and Technology



HU Charles
Founder, Ryoden Medical
Holdings Limited and Co-
founder, Incando Therapeutics



JE Simon
Chairman of the Board, Great
Treasure International / Galaxy
Treasure Group



JIANG Ru Hong
Founder, CEO, President and
Director,
ASC Therapeutics, Inc.



JIANG Claire
CEO, Queens (Shenzhen)
Biotechnology Co., Ltd.



JIN Kewen
Managing Partner & Co-founder,
Serica Capital



LAW Philip
Technology, Media and
Technology Leader, Hong Kong,
Deloitte



LE DEU Franck
Senior Partner, Head of Greater
China, McKinsey & Company



LEE Tin Lap
Associate Professor, School of
Biomedical Sciences, Faculty of
Medicine, The Chinese University
of Hong Kong



LEUNG Chuen Yan
Vice President, Portfolio
Management and
Research



LEUNG Yun Chung, Thomas
Lo Ka Chung Charitable Foundation
Professor in Pharmaceutical
Sciences Professor and DoULS



LI James
President, Li Law Inc.



LI Xiao Yi, Benjamin
CEO, Lee's
Pharmaceutical Holdings
Limited



LI Ying
Chair Professor of
Neuroscience,
City University of Hong Kong




LIN Mindin
CEO & Editor in Chief,
Global Bio & Investment
Monthly



LIU Andy
CEO, CW Data
Technologies



LO Kitty
Chairman and CEO,
Finet Group Ltd.



LO Yuk Lam
Chairman, Food and Environmental
Hygiene, Food and Health Bureau,
Government Secretariat HKSAR



LU Ming Hua
Founding Partner,
eChinaHealth



LYU Ai Ping
Dean and Chair Professor, Dr.
Kennedy Y.H. Wong Endowed

Organizing Committees (2)



MOK Kin Lun, John
Chairman of AML Holdings Limited



MONTELIUS Lars
Director General, International Iberian Nanotechnology Laboratory



NEARING Kimberly
Board of Directors, The BayHelix Group



NGUYENPHUOC Donna
Partner, SPARQ Capital



ORR Kevin
Vice President, Winner Medical Group



PAN Wendy, JD
Board of Directors, The BayHelix Group



PEI Duan Qing
Principle Investigator and Academic Director at the Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences



QIAN Pei Yuan
Head and Chair Professor, Department of Ocean Science, Hong Kong University of Science and Technology



SEGERBLOM Bjorn
Honorary Chairman and Hong Kong Representative, International Iberian Nanotechnology Laboratory



SHANG Hai Long
Managing Director, Sense Time Hong Kong



SHI Victor
CEO, Adicon Clinical Laboratories



SIU Eric
Chairman of the Hong Kong Center, Macau International Healthcare Think Tank



SUN Fei
Assistant Professor, Chemical and Biological Engineering, The Hong Kong University of Science and Technology



SUN Nan
Deputy Inspector, Shenzhen Association for Science and Technology



SUN-Hoffman Lin
Head of the North California Division, BayHelix



TANG C. Mark
Managing Director, Good Health Capital (New York)



TIAN Yao Lin
CEO, Shenzhen Govita Medical Laboratory



TSIM Wah Keung, Karl
Director, Centre for Chinese Medicine R & D



TSUI Victor
Chief Operating Officer, Powder Pharmaceuticals Incorporated



UHLEN Mathias
President, European Federation of Biotechnology



WAN Mu Maki
Immediate Past President, Rotary Club Kowloon Golden Miles



WAN Mu Maki
Assistant Professor, Division of Life Science, The Hong Kong University of Science and Technology



WANG Jing
Centre for Advanced Measurement Science, National Institute of Metrology, China



WANG Yitao
Director, Institute of Chinese Medical Sciences



WONG Anny
CEO, AlphaSmart World Limited



WONG Bing Lou
Adjunct Professor, Department of Biochemistry, Chinese University of Hong Kong



WONG Taam Chi Woon, Vivian
Hon Professor, School of Chinese Medicine, The University of Hong Kong



WONG Ying Ho, Kennedy
Managing Partner & Attesting Officer, Philip K H Wong, Kennedy Y H Wong & Co.

Organizing Committees (3)



XIE Jia Sheng
Director & Executive President,
Guangdong Medical Valley
(GDMV)



XIE Min, Robert
CEO, Asia Investment Fund
Management Limited



YANG Haiding
Executive Director and
Medical Team Leader of
Cathy Capital



YANG Meng Su, Michael
Head and Yeung Kin Man Chair
Professor, Department of Biomedical
Sciences, City University of Hong Kong



YANG Ray
Partner, Marathon Venture Partners



YANG Steve
Chief Business Officer &
Executive Vice President,
WuXi AppTec Co., Ltd.



YU Duncan
President, MGI



YUNG Kin Lam, Ken
Professor and Associate Head,
Faculty of Science,
Hong Kong Baptist University



ZHANG Jimmy
Founding Member and
Former Chairman of
BayHelix Group



ZHENG Lili
Partner, Deloitte Tax LLP



ZHOU Guo Ying, Grace
President, Shenzhen International
Institute for Biomedical Research

BIOHK2021 Team



Nancy CHUENCHAI

Project Manager
Hong Kong Biotechnology
Organization

BSc (Hons) in Convention
and Event Management
School of Hotel and
Tourism Management
The Hong Kong
Polytechnic University



Dior LAI

Operations Manager
Hong Kong Biotechnology
Organization

BSc (Hons) in Convention
and Event Management
School of Hotel and
Tourism Management
The Hong Kong
Polytechnic University



Louvinia WONG

Project Officer
Hong Kong Biotechnology
Organization

Biological Sciences BSc
(Hons) (Physiology with
Pharmacology and
Neuroscience)
University of Leicester



Chris CHOW

Sales Executive
Hong Kong Biotechnology
Organization

BSc (Hons) in Tourism
Management
School of Hotel and
Tourism Management
The Hong Kong
Polytechnic University



Ryan LUNG

Marketing Officer
Hong Kong Biotechnology
Organization

Aerospace Engineering
BEng (Hons)
University of Liverpool



George CHAN

Management Information
Systems Manager
Hong Kong Biotechnology
Organization

BEng in Computer Science
Hong Kong University of
Science and Technology

Organizers



Co-organizers

全面展會管理



Diamond Sponsors

Deloitte.



Special Supporting Organizations



創新及科技局
Innovation and Technology Bureau



創新科技署
Innovation and
Technology Commission



漁農自然護理署
Agriculture, Fisheries and
Conservation Department

Supporting Organizations



Global Partners



Media Partners



Official Hotel Partner



Official Carrier



Conclusion

BIOHK will open a new era in biotechnology in Hong Kong.

Join us at this event to witness the start of a new wave of innovations that will benefit well-being worldwide.

Please contact us and we will be happy to help you to
plan your BIOHK experience!

Thank You!

Contact

Website: bio-hk.com Email: info@bio-hk.com
Tel: +852 2799 7688 Fax: +852 2111 9762



Scan and Find us



BIOHK2021
香港國際生物科技展



Appendix

BIOHK2021
香港國際生物科技展

Appendix I: About the Organizers



Hong Kong Biotechnology Organization (HKBO) established in 2010 by reputable industry and esteemed academic representatives, is a non-profit organization which continuously strives to promote Hong Kong as the biotech hub of Asia. HKBO has organized and sponsored several successful events in the past that highlighted the substantial potential of Hong Kong's Biotechnology sector.



The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members.



Ausvic Capital ("Ausvic") is a global biotech, Artificial Intelligence (AI) and cloud computing-focused investment group founded by Mr. Chen Ping and a group of leading investors in 2018. Mr. Chen and his team began their track record of successful biotech and AI investing globally and the founding partners all have a deep root in entrepreneurship in China and globally. Today, Ausvic leverages its extensive network around the world and focused on some of the world's most novel life science and AI-related companies and technologies in the United States, Europe, and China.

Appendix II: About HKBIO

HKBIO's Past Events

2018 Hong Kong Biotech Horizons

A mobile conference with the aim of promoting biotech and connecting professionals from a cross section of industries to create a diverse network that can foster the biotech industry's development and innovation.

2017 Hong Kong Biotech Horizons

"Global Congress on Biotechnology: Diagnostics and Therapeutics" brought together communities of scientific researchers, technology developers and entrepreneurs seeking progress in translational science.

HKBIO Horizon Series

12th International Conference on Brain Energy Metabolism-linked leading experts and young, emerging neuroscientists worldwide, all interested in diverse aspects of brain energy metabolism.

HKBIO Cancer Research Fund

Dedicated to furthering the cause of preventing and curing cancer by promoting clinical cancer research in Hong Kong and China.

Appendix III:

Biotechnology Trends in 2021

- Out of China's 199 science parks, 111 are biotechnology parks, with 93 concentrated in the Guangzhou area.
- Some USD45 billion was invested in biotech companies in China between 2014-2017 – more than USD12 billion of it coming from Chinese venture capital and other private firms.
- China's DNA sequencing market is expected to grow to 18.3 billion RMB by 2022 from 7.2 billion RMB last year, greatly surpassing the overall global market because of the country's rising income and growing investments in health care infrastructure.
- Hong Kong Stock Exchange's biggest listing reform in 25 years (effective 30 April 2018) saw the establishment of a new Biotech chapter allowing biotech companies that are pre-revenue or insufficiently profitable to be listed — transforming Hong Kong into the world's second largest biotechnology listing platform.
- Out of the top Asia-Pacific IPOs in 2016, four of the top five were China based biotech companies.
- Guangdong, Hong Kong and Macao – (key regions in the Greater Bay Area (GBA) established in 2017) promoted joint and coordinated regional economic development.

Appendix IV:

Topics for the Convention

- 5G + Data Transmission
- AI + Biotech
- Anti-ageing
- Antibiotics & Antimicrobial Resistance
- Applications of Bioengineering
- Bioethics, Law & Investment
- Biotech in Guangdong-HK-Macau GBA
- Biotech in Society and Culture
- Biotech IPO + HKEX
- Block Chain + Biotech
- Business Development & Emerging
- Opportunities in Biotech
- Cancer Therapies
- Cardiovascular Diseases, Therapies & Diagnostics
- Clinical Trials
- Diagnostics & Medical Devices
- Digitization of Healthcare
- Environmental Biotechnology
- Genome Editing and Gene Therapy
- Glioblastoma
- Global Cell & Gene Therapeutics and Regulatory Trends
- Infectious Diseases and Vaccines
- Intellectual Property Rights
- International Strategic Perspectives
- Lab-on-a-chip
- Marine Biotechnology
- Medical Device Market Penetration
- Microbiome & Probiotics
- Modernization of Chinese Medicine
- New Drug Discovery
- New Therapies
- Oncology
- One Belt One Road
- Pharma
- Precision Medicine and Big Data
- Present and Future Bioethics
- Public Health
- Rare Diseases
- Regenerative Medicine & Immunology
- Stem Cell Research
- Translational Medical Genomics
- And More...

Appendix V:

Hong Kong Being the Key Strategic Role

- Hong Kong Exchanges and Clearing Limited has enabled pre-revenue biotech companies to be listed on the Main Board – a milestone in stock market history
- Innovation and Technology (I&T) fund has financed over 540 biotech projects and aims to attract more world-class scientific research institutions & technology enterprises
- About 1,300 I&T companies and “incubates” have established themselves in the Hong Kong Science Park (HKSP) and Cyberport
- Currently, the city has approximately 250-300 biotech-related companies
- Hong Kong is a preferred destination for multinationals to set up offices and regional headquarters
- Hong Kong’s start-up scene has experienced phenomenal growth in recent years
- Several incubators and accelerators offer start-ups comprehensive incubation programs to promote the local biotech scene

Appendix VI: Hong Kong Offers

- Active entrepreneurial ecosystem
- Free & open economy
- Gateway to vast China market
- Excellent fund-raising platform
- Established financial & legal systems
- Sound regulatory regime
- Transparent vetting process
- IP protection
- Business friendly taxes
- Innovation & Technology (I&T) fund
- Reputable quality control & assurance
- A supportive government